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Studies on anthelmintic activity of medicinal plants have received insufﬁcient interest and attention from researchers despite the high incidence
of helminth infections in the poorer communities of South Africa. There are only a few anthelmintic remedies available which are inadequate in
terms of accessibility, affordability and probably efﬁcacy. In this review, we reappraised the various anthelmintic studies on South African
medicinal plants to highlight how much and/or how little is known. The rich botanical and medicinal plant knowledge in South Africa is an
indication of the potential of discovering potent treatments against helminth diseases in both humans and livestock. A total of 115 plant species
encompassing 43 families screened for their anthelmintic potential (mainly nematodes) are listed in the current review. Combretaceae and Fabaceae
were the most commonly used families. Tetradenia riparia, Hypoxis colchicifolia, Apodytes dimiata and Leucosidea sericea are a few examples of
the South African species that have demonstrated promising anthelmintic activity. Even though other species such as Dicerocaryum eriocarpum,
Berchemia zeyheri and Acorus calamus are potent anthelmintics, caution must be exercised in administering these plant extracts because of their
potential toxic effects. Besides the beneﬁt of validating the efﬁcacy of traditional medicines, compounds from South African medicinal plants
could also provide a template for novel synthetic anthelmintics. However, the major bottleneck in exploring more South African medicinal plants
for anthelmintic properties is probably the lack of a robust, rapid and reliable screening technique as well as adequate funding schemes. Perhaps,
there could be more success stories via increased research outputs with the development and availability of high throughput screening methods for
assessing the activity of these medicinal plants as well as their resultant bioactive compounds. In addition, accessibility of funds to acquire latest
technology and motivate researchers will inevitably stimulate more studies geared toward alleviating the problems posed by helminth infections.
© 2012 SAAB. Published by Elsevier B.V. All rights reserved.
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for national governments to encourage more research into
traditional medicinal plants and emphasized the importance of
developing good policies, regulations and trade standards. Along
this line, the South African government has proposed the
integration of traditional medicine into the national healthcare
system. However, the absence of stringent regulation mechanisms
and secrecy within traditional medicine remains major stumbling
blocks (Gqaleni et al., 2007). Jäger (2005) raised concern on the
relatively limited research focusing on diseases such as diarrhea,
schistosomiasis and other helminthiasis affecting the majority of
the population who are the main users of traditional medicine. For
instance, only a few research groups such as the Research Centre
for Plant Growth and Development, University of KwaZulu-Natal
and the Phytomedicine Programme, Department of Paraclinical
Sciences, University of Pretoria, have been actively involved in
anthelmintic research. Furthermore, the lack of regulation in the
prescription and usages of traditional medicines as well as
inadequate toxicological evidence on the safety of the medicinal
plants remain a problem (Fennell et al., 2004; Verschaeve andVan
Staden, 2008). Most importantly, there needs to be a holistic
approach for traditional medicine that creates avenues to channel
scientific information back to traditional healers (Jäger, 2005).
Helminth infections of both humans and livestock are of
considerable importance (Hoste and Torres-Acosta, 2011).
Anthelmintics dominate the animal pharmaceutical industry
being sold in the largest volume and having a high value (see
International Federation for Animal Health website: http://www.
ifahsec.org). Anthelmintic research and development has thus
demanded a very large share of the animal health pharmaceutical
development effort and is probably the only area of such research
where efforts and success in animal health exceed those in human
health (McKellar and Jackson, 2004).
In this review, we highlight the limited available scientific
data on helminth diseases in both humans and livestock despite
the significant problems associated with the infections. In
addition, the various techniques and safety of the South African
medicinal plants screened for their anthelmintic properties in
recent years (up till January 2012) are assessed. The review isexpected to serve as an impetus for more studies to explore the
rich South African flora.
2. Helminth infections and associated problemsHelminth infections such as ascariasis, hookworm infection and
schistosomiasis constitute the core 13 neglected tropical diseases
(NTDs) affecting the world population (Hotez et al., 2007).
Majority of the NTDs are well-pronounced among impoverished
populations living in marginalized regions (Hotez et al., 2009). In
most developing countries, helminth infections have remained a
major health concern because factors that pre-dispose humans to
these infections abound in these areas. These incapacitating
diseases continue to inflict severe disability and often death. In
terms of disability-adjusted life years (DALYs), Hotez et al. (2006)
estimated the global burden of helminth infections to be 39 million
life years which is comparable to tuberculosis (34.7 million
DALYs) and malaria (46.5 million DALYs), the two major
human infectious diseases associated with high mortality rates.
As a result, helminthiases have generally become the indices of
low levels of socio-economic status of the countries where the
infections are prevalent (Hotez et al., 2009). Children, especially
those less than five years old, have been identified as the most
vulnerable group with high rates of helminth infection (Sinniah,
1984).
The infecting helminth species, degree of infection and host
age, determine the clinical symptoms of helminth infection (Wang
et al., 2008). A number of factors that determine the pathogenicity
of helminth infections include: exposure and entry; adherence and
replication; cell and tissue damage; disruption, invasion and
inactivation of host defenses (Murray et al., 1998). Researchers
have also observed a decline in host immune status as a result of
helminth infection thereby increasing the host susceptibility to
other pathogens and secondary infections (Borkow and Bentwich,
2006; Brooker et al., 2004). Increasing direct and indirect
evidences has indicated that helminth infection create an
opportunity for more rapid infection by the human immunodefi-
ciency virus (HIV) as well as quicker progression to acquired
immune-deficiency syndrome (AIDS) and tuberculosis. In addi-
tion, the efficacy of some vaccines against HIV may be impaired
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2003; Wolday et al., 2002). Ironically, studies have indicated that
ailments such as asthma, heart and Crohn's diseases could be
suppressed by some groups of helminths (Elliott et al., 2007;
Magen et al., 2005). Consequently, it has been predicted that the
concept of some helminths may change from that of a strict parasite
– harmful to the host, to a mutualist – providing benefit to the host
as governors of immune-mediated inflammation in the near future
(Elliott et al., 2007). Active research to support this theory is on-
going but it is outside the scope of this review.
Due to the asymptomatic nature of helminth diseases, they can
remain undetected and children born in an endemic region may
harbor the worms for the greater parts of their lives (WHO, 1987).
Majority of the helminths consume nutrients from their host,
thereby causing or aggravating malnutrition which results in
retarded growth and physical development. Consequently, symp-
toms like retarded cognitive development, iron deficiency anemia,
abdominal pains and related health problems are characteristic
features of most heavy helminth infections (Kirwan et al., 2009).
Generally, helminth infections are regarded as a global problem of
medical, educational and economic significances because of the
long term chronic inflammatory disorders and disabling effects
when left untreated (Prichard et al., 2012; Stepek et al., 2006;
Wang et al., 2008).
2.1. Prevalence of helminth infections in South Africa
In South Africa, especially the rural areas, the prevalence rate
of helminth infections is alarming because factors such as poor
sanitation and malnutrition that pre-dispose humans to these
infections abound. Although there is no official data on prevalence
and intensity of helminth infections in the country as a whole
(Fincham et al., 1996; Schutte et al., 1995), incidence of high
prevalence rate of intestinal nematode infection in Mpumalanga
(Evans et al., 1987), the Western Cape (Fincham et al., 1996) and
KwaZulu-Natal (Appleton et al., 1999; Mabaso et al., 2004) have
been reported. Of particular interest is KwaZulu-Natal, the third
poorest province in South Africa, which has a high mortality and
prevalence of HIV/AIDS (Hirschowitz and Orkin, 1997). In
KwaZulu-Natal, the transmission and epidemiology problems of
helminth infections such as Ascaris lumbricoides and Trichuris
trichiura have remained relatively high over a long period of time
(Jinabhai et al., 2001) and children remain the most vulnerable
group (Saathoff et al., 2004).
As with helminth infection rates in humans (Mkhize-Kwitshana
et al., 2011), the absence of prevalence surveys in recent times
makes it difficult to substantiate the postulated high incidence rate
in South Africa (Kaplan and Vidyashankar, 2012). As is common
in the tropics, Haemonchus contortus and Trichostrongylus
colubriformis remain the most common nematodes that hinder
production of ruminants in South Africa (Horak and Ursula, 2004;
Van Wyk et al., 1999). Helminthiasis is often controlled with the
use of chemotherapeutics; however, the development of resistance
to most of the commercially available anthelmintics has become a
severe problem globally (Hoste and Torres-Acosta, 2011). In fact,
the first case of anthelmintic resistance (against ivermectin) was
reported in South Africa (Van Wyk et al., 1987).3. Limitations of existing treatment regimes
3.1. Available classes of anthelmintic drugs and their mode of
action
The existing pharmacopeia for both human and livestock
helminth infections is severely limited (Geary et al., 2010). The
control of helminth infections requires a multi-faceted approach
due to the complex life cycles of the causative organisms as well
as environmental influences (Hoste and Torres-Acosta, 2011;
Whitfield, 1996). Currently, the use of broad spectrum chemo-
therapy is required for multiple worm infection in humans (Booth
et al., 1998) and livestock (Hoste and Torres-Acosta, 2011). In
addition, proper health education, good hygiene and improved
sanitation are indispensable in alleviating the spread of the
causative organisms (Fincham et al., 2003; Savioli et al., 1992;
Stepek et al., 2006).
Based on their chemical structure and mode of action, there are
only four classes of anthelmintics. The Class 1 drugs, known as the
benzimidazoles (e.g. albendazole and mebendazole) were intro-
duced in 1961. These drugs bind to free beta-tubulin and inhibit
its polymerization, thereby interfering with the microtubule-
dependent glucose uptake by the parasite (Rang et al., 2003).
Class 2 imidazothiazole drugs e.g. levamisole, were discovered in
1966 and act by stimulating the nicotinic acetylcholine receptors
leading to the paralysis of the worms which are subsequently
washed out of the intestine by peristalsis (Stepek et al., 2006).
The third class of drugs, generally referred to as macrocyclic
lactones, were introduced in the early 1980s (Chabala et al.,
1980). The first of such drugs was ivermectin which interferes
with GABA-mediated neurotransmission resulting in paralysis
and death of the helminth. These drugs act by paralysis of body-
wall muscles in nematodes (Behnke et al., 2008). In 1997,
moxidectin, an analogue of ivermectin, which is the most potent
macrocyclic lactone, was developed due to incidences of
resistance and ineffectiveness of ivermectin against some groups
of helminths (Geary, 2005). The limited potency and safety of the
three classes necessitated the search for new anthelmintics
(Whitfield, 1996). Finally in 2009, Novartis launched Zolvix®,
a new class of anthelmintic referred to as the amino-acetonitrile
derivatives (AADs) after 28 years of intensive research
(Kaminsky et al., 2008b). The AADs interfere with a unique
ACR-23 nicotinic acetylcholine receptor subunit leading to the
paralysis of the worms. In addition, AADs are relatively safe as
evident from their low toxicity to mammals after various tests
(Ducray et al., 2008; Kaminsky et al., 2008a). Further studies by
researchers involve the possibility of the potential synergetic
action of different drugs (Tritten et al., 2012a,c). In view of the
wide diversity of helminthiasis and scope of the current review,
more details on available chemotherapeutics, especially against
other group of helminths such as cestodes and trematodes are
available elsewhere (Geary et al., 2010).
3.2. Rationale for exploring alternative treatments
‘Global worming’ is evident in countries such as South Africa,
United States, Brazil and New Zealand (Kaplan and Vidyashankar,
Table 1
Examples of South African medicinal plants screened for their anthelmintic potential.
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Alliaceae (Liliaceae)
Tulbaghia violacea Harv. Tb DBA –
in vitro
Caenorhabditis elegans 1.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003; Reid et al., 2006);
and positive – micronucleus test (Taylor et al., 2003)
McGaw et al.
(2000)
Amaranthaceae
Amaranthus hybridus L. L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Anacardiaceae
Rhus geinzii Sond R DBA –
in vitro
Schistosoma
haematobium
50.0 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003)
Sparg et al.
(2000)
Rhus lancea L.f. Bk
L
DBA –
in vitro
C. elegans 1.00
0.50
Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Sclerocarya birrea (A.
Rich.) Hochst.
R DBA –
in vitro
S. haematobium 25.0 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and brine
shrimp toxicity assay (McGaw et al., 2007)
Sparg et al.
(2000)
Sclerocarya birrea (A.
Rich.) Hochst.
Bk DBA –
in vitro
C. elegans 0.50 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and brine
shrimp lethality/toxicity
(McGaw et al., 2007)
McGaw et al.
(2007)
Apiaceae
Hetermorpha trifoliata
(Spreng.) Cham. &
Schltdl.
L DBA –
in vitro
C. elegans 2.00 Negative – Ames and VITOTOX® (Elgorashi et al., 2003);
and positive – micronucleus test and comet assay
(Taylor et al., 2003)
McGaw et al.
(2000)
Pimpinella caffra (Eckl.
& Zeyh.) D. Dietr.
Wp DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
Apocynaceae
Acokanthera oblongifolia
(Hochst.) Codd
L DBA –
in vitro
C. elegans n/a Negative – Ames and VITOTOX®
(Elgorashi et al., 2003)
McGaw et al.
(2000)
Acokanthera
oppositifolia (Lam.)
Codd
L
T
CA –
in vitro
C. elegans 0.52
2.08
Unknown Aremu et al.
(2010b)
Asclepias fruticosa L. L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Landolphia kirkiiDyer ex
Hook. f.
– DBA –
in vitro
S. haematobium 25.0 Sparg et al.
(2000)
Mondia whitei (Hook. f.)
Skeels
R DBA –
in vitro
S. haematobium 25.0 Unknown Sparg et al.
(2000)
Secamone filiformis (L.f.)
J.H. Ross.
Ap DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Thevetia peruviana
(Pers.) K. Schum
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Araceae
Acorus calamus L. R+Rm DBA –
in vitro
C. elegans 1.00 Positive – brine shrimp toxicity assay
(Padmaja et al., 2002)
McGaw et al.
(2000)
Araliaceae
Cussonia spicata Thunb. R DBA –
in vitro
C. elegans n/a Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Asteraceae
Artemisia afra Jacq. ex
Willd.
L DBA –
in vitro
C. elegans 1.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and micronucleus test
(Taylor et al., 2003)
McGaw et al.
(2000)
Berkheya speciosa (DC.)
O. Hoffm.
R DBA –
in vitro
S. haematobium 3.13 Unknown Sparg et al.
(2000)
Brachylaena discolor
DC.
L DBA –
in vitro
C. elegans 1.00 Negative – toxicity to hepatocytes
(Chang liver) and adipocytes (3T3–L1) cells
(Van de Venter et al., 2008)
McGaw et al.
(2000)
Felicia erigeroides DC. L
S
CA –
in vitro
C. elegans 0.52
2.08
Unknown Aremu et al.
(2010b)
Hertia pallens (DC.)
Kuntze
L DBA –
in vitro
C. elegans 1.00 Positive – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Schkuhria pinnata (Lam.)
Kuntze ex Thell.
Ap DBA –
in vitro
C. elegans 1.00 Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
(continued on next page)
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Table 1 (continued)
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Vernonia colorata
(Willd.) Drake
R DBA –
in vitro
S. haematobium 50.0 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003);
and positive (toxic) – micronucleus test
and comet assay (Taylor et al., 2003)
Sparg et al.
(2000)
Bignoniaceae
Kigelia africana (Lam.)
Benth.
L DBA –
in vitro
C. elegans 1.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003)
McGaw et al.
(2000)
Markhamia obtusifolia
(Baker) Sprague.
L DBA –
in vitro
Trichostrongylus
colubriformis
0.46 (EC50) Negative – Vero monkey kidney cell
line cytotoxicity assay (Nchu et al., 2011)
Nchu et al.
(2011)
Cactaceae
Cereus jamacaru DC. Ap DBA –
in vivo
Haemonchus contortus
T. colubriformis
n/a Negative – toxicity to hematological
and biochemical parameters
(Messias et al., 2010)
Vatta et al.
(2011)
Combretaceae
Combretum apiculatum
Sond.
L DBA –
in vitro
C. elegans
S. haematobium
0.5
n/a
Positive – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum bracteosum
(Hochst.) Brandis
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum celastroides
Welw. ex M.A. Lawson
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum collinum
Fresen.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum edwardsii
Exell
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum
erythrophyllum (Burch.)
Sond.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum hereroense
Schinz
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Positive – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum imberbe
Wawra
L DBA –
in vitro
C. elegans
S. haematobium
n/a
12.5
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum imberbe
Wawra
R DBA –
in vitro
S. haematobium 12.5 Negative – biochemical induction assay
(McGaw et al., 2001)
Sparg et al.
(2000)
Combretum kraussii
Hochst.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
12.5
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum
microphyllum Klotzsch
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum mkhzense
J.D. Carr & Retief
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum moggii Exell L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum molle R.Br.
ex G. Don
L DBA –
in vitro
H. contortus 0.066 (LD50) Negative – biochemical induction assay
(McGaw et al., 2001)
Ademola and
Eloff (2010)
Combretum molle R.Br.
ex G. Don
L DBA –
in vitro
C. elegans
S. haematobium
n/a
25
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum
mossambicense
(Klotzsch) Engl.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Positive – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum nelsonii
Duemmer
L DBA –
in vitro
C. elegans
S. haematobium
n/a
12.5
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum padoides
Engl. & Diels
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum paniculatum
Vent.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
25
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum petrophilum
Retief
L DBA –
in vitro
C. elegans
S. haematobium
n/a
25
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum woodii
Duemmer
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Combretum zeyheri
Sond.
L DBA –
in vitro
C. elegans
S. haematobium
n/a
n/a
Negative – biochemical induction assay
(McGaw et al., 2001)
McGaw et al.
(2001)
Cornaceae
Curtisia dentate
(Burm.f.) C.A.Sm.
L DBA –
in vitro
C. elegans
H. contortus
T. colubriformis
0.160
0.310
0.160
Unknown Shai et al.
(2009)
138 AO. Aremu et al. / South African Journal of Botany 82 (2012) 134–150
Table 1 (continued)
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Crassulaceae
Cotyledon orbiculata L.
var. dactylopsis
L
S
CA –
in vitro
C. elegans 0.26
4.17
Negative – acute mammalian toxicity test
(Amabeoku and Kabatende, 2012)
Aremu et al.
(2010b)
Cotyledon orbiculata L.
var. orbiculata
L
S
CA –
in vitro
C. elegans 0.26
4.17
Negative – acute mammalian toxicity test
(Amabeoku and Kabatende, 2012)
Aremu et al.
(2010b)
Crassula multicava
Lemaire.
Wp CA –
in vitro
C. elegans 0.008 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Cyatheaceae
Cyathea dregei Kunze L
R
CA –
in vitro
C. elegans 0.52
2.08
Unknown Aremu et al.
(2010b)
Dracaenaceae (Liliaceae)
Sansevieria
hyacinthoides (L.) Druce
L DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
Ebenaceae
Euclea divinorum Hiern. Bk DBA –
in vitro
C. elegans 1.00 Positive (toxic) – Ames and VITOTOX®
(Elgorashi et al., 2003)
McGaw et al.
(2000)
Euclea divinorum Hiern. R DBA –
in vitro
S. haematobium 25.0 Positive (toxic) – Ames and VITOTOX®
(Elgorashi et al., 2003)
Sparg et al.
(2000)
Euclea natalensis A.DC. Bk DBA –
in vitro
S. haematobium 3.13 Positive (toxic) – Ames and VITOTOX®
(Elgorashi et al., 2003); and negative –
micronucleus and comet assay
(Taylor et al., 2003)
Sparg et al.
(2000)
Euphorbiaceae
Antidesma venosum E.
Mey. ex Tul.
R DBA –
in vitro
S. haematobium 12.5 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003). Positive –
micronucleus test and comet assay
(Taylor et al., 2003)
Sparg et al.
(2000)
Jatropha multifida L. L DBA –
in vitro
C. elegans 1.00 Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Ricinus communis L. L DBA –
in vitro
C. elegans 1.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and positive –
brine shrimp toxicity assay (McGaw et al., 2007)
McGaw et al.
(2000)
Ricinus communis L. S+L DBA –
in vitro
C. elegans 1.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and positive –
brine shrimp toxicity assay (McGaw et al., 2007)
McGaw et al.
(2007)
Ricinus communis L. R DBA –
in vitro
S. haematobium 25.0 Positive – micronucleus test (Taylor et al., 2003) Sparg et al.
(2000)
Synadenium cupulare
(Boiss.) L.C. Wheeler.
S+L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Fabaceae
Abrus precatorius L. R DBA –
in vitro
S. haematobium 6.25 Unknown Sparg et al.
(2000)
Acacia karoo Hayne – DBA –
in vitro
S. haematobium 50.0 Positive/negative – acute and sub-acute
mammalian toxicity tests (Adedapo et al., 2008)
Sparg et al.
(2000)
Afzelia quanzensis Welw. R DBA –
in vitro
S. haematobium 6.25 Negative – Ames and VITOTOX®,
(Elgorashi et al., 2003); and micronucleus
test and comet assay (Taylor et al., 2003)
Sparg et al.
(2000)
Albizia adianthifolia
(Schumach.) W. Wight
L DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
Albizia versicolor Welw.
ex Oliv.
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Elephantorrhiza
elephantina (Burch.)
Skeels
R DBA –
in vivo
Strongyle
Trichuris spp.
Eimeria spp.
500 mg/kg Negative – acute, sub-acute and chronic
mammalian toxicity tests (Maphosa et al., 2010a)
Maphosa and
Masika
(2012)
Elephantorrhiza
elephantina (Burch.)
Skeels
R DBA –
in vitro
H. contortus 2.50 Negative – acute, sub-acute and chronic
mammalian toxicity tests (Maphosa et al., 2010a)
Maphosa et al.
(2010b)
Erythrophleum
lasianthum Corbishley
L DBA –
in vitro
C. elegans 2.00 Unknown McGaw et al.
(2000)
Leucaena leucocephala
(Lam.) de Wit
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Medicago sativa L. L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
(continued on next page)
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Table 1 (continued)
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Peltophorum africanum
Sond.
L
Bk
R
DBA –
in vitro
H. contortus 5.0
5.0
1.0
Negative – brine shrimp toxicity assay;
and Vero monkey kidney cells
cytotoxicity assay (Bizimenyera, 2007)
Bizimenyera
et al. (2006b)
Peltophorum africanum
Sond.
Rb DBA –
in vivo
H. contortus
T. colubriformis
n/a Negative – brine shrimp toxicity assay;
and Vero monkey kidney cells cytotoxicity assay
(Bizimenyera, 2007)
Bizimenyera
et al. (2008)
Peltrophorum africanum
Sond.
L
Sb
Rb
DBA –
in vitro
T. colubriformis 0.619 (ED50)
0.383 (ED50)
0.280 (ED50)
Negative – brine shrimp toxicity assay;
and Vero monkey kidney cells cytotoxicity assay
(Bizimenyera, 2007)
Bizimenyera
et al. (2006a)
Pseudarthria hookeri
Wight & Arn.
L+R DBA –
in vitro
S. haematobium 50.0 Unknown Sparg et al.
(2000)
Pterocarpus angolensis
DC.
Bk
L
DBA –
in vitro
C. elegans 1.00
2.00
Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Schotia brachypetala
Sond.
Bk
L
DBA –
in vitro
C. elegans 1.00
2.00
Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Senna petersiana (Bolle)
Lock.
L CA –
in vitro
C. elegans 0.52 Positive – Vero monkey kidney cell line
cytotoxicity test (Tshikalange et al., 2005)
Aremu et al.
(2010b)
Senna petersiana (Bolle)
Lock.
— DBA –
in vitro
S. haematobium 6.25 Positive – Vero monkey kidney cell line
cytotoxicity test (Tshikalange et al., 2005)
Sparg et al.
(2000)
Hypoxidaceae
Hypoxis colchicifolia
Bak.
L
C
CA –
in vitro
C. elegans 0.13
2.08
Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and positive –
micronucleus test and comet assay (Taylor et al., 2003)
Aremu et al.
(2010b)
Hypoxis hemerocallidea
Fisch., C.A. Mey. & Avé-
Lall.
L
C
CA –
in vitro
C. elegans 1.04
1.04
Negative – Ames test and VITOTOX®
(Elgorashi et al., 2003; Reid et al., 2006);
and positive – micronucleus test (Taylor et al., 2003)
Aremu et al.
(2010b)
Icacinacea
Cassinopsis illicifolia
Hochst.
L
Bk
CA –
in vitro
C. elegans 0.033
0.016
Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Apodytes dimidiate E.
Mey. ex Arn.
L DBA –
in vitro
C. elegans 1.00 Negative – acute and sub-acute
mammalian toxicity tests (Brackenbury et al., 1997)
McGaw et al.
(2000)
Lamiaceae
Leonotis leonurus (L.)
R.Br.
L DBA –
in vivo
Strongyle
Trichuris spp.
Eimeria spp.
500 mg/kg Positive/negative – acute, sub-acute
and chronic mammalian toxicity tests
(Maphosa et al., 2008)
Maphosa and
Masika
(2012)
Leonotis leonurus (L.)
R.Br.
L DBA –
in vitro
H. contortus 1.25 Positive/negative – acute, sub-acute and chronic
mammalian toxicity tests (Maphosa et al., 2008)
Maphosa et al.
(2010b)
Leonotis leonurus (L.)
R.Br.
L DBA –
in vitro
C. elegans 1.00 Positive/negative – acute, sub-acute and chronic
mammalian toxicity tests (Maphosa et al., 2008)
McGaw et al.
(2000)
Ocimum basilicum L. L CA –
in vitro
C. elegans 0.26 Negative – acute and sub-acute mammal toxicity
(Fandohan et al., 2008)
Aremu et al.
(2010b)
Tetradenia riparia
(Hochst.) Codd
L CA –
in vitro
C. elegans 0.004 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Malvaceae
Gossypium herbaceum L. L DBA –
in vitro
C. elegans 1.00 Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Meliaceae
Ekebergia capensis
Sparrm.
L DBA –
in vitro
C. elegans 2.00 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003; Reid et al., 2006);
and toxic – micronucleus test
(Taylor et al., 2003)
McGaw et al.
(2000)
Melia azedarach L. L DBA –
in vitro
C. elegans 1.00 Positive – review studies (Phua et al., 2008) McGaw et al.
(2000)
Trichilia emetic Vahl. – DBA –
in vitro
S. haematobium 3.13 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); Positive –
Micronucleus test (Taylor et al., 2003)
Sparg et al.
(2000)
Melianthaceae
Melianthus comosus
Vahl.
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Melianthus major (L.) L DBA –
in vitro
C. elegans n/a Positive – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Myrsinaceae
Maesa lanceolata Forssk. L DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
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Table 1 (continued)
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Olacaceae
Ximenia caffra Sond. R DBA –
in vitro
S. haematobium 50.0 Positive – antiproliferative assay with three
human cell lines (HeLa, HT29 and A431)
(Kamuhabwa et al., 2000)
Sparg et al.
(2000)
Pedaliaceae
Dicerocaryum
eriocarpum (Decne.)
Abels
Wp DBA –
in vitro
C. elegans 1.00 Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Poaceae
Sorghum bicolor (L.)
Moench
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Ranunculaceae
Clematis brachiate
Thunb.
L+S DBA –
in vitro
S. haematobium 25.0 Positive/negative – toxicity to mammalian liver,
kidney and hematological parameters
(Afolayan et al., 2009)
Sparg et al.
(2000)
Rhamnaceae
Berchemia zeyheri
(Sond.) Grubov
Bk DBA –
in vitro
C. elegans 0.50 Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Ziziphus mucronata
Willd.
Bk
L
DBA –
in vitro
C. elegans n/a
n/a
Positive – Ames and VITOTOX®
(Elgorashi et al., 2003); micronucleus test
and comet assay (Taylor et al., 2003);
and brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Ziziphus mucronata
Willd.
R DBA –
in vitro
S. haematobium 12.5 Positive – Ames and VITOTOX®
(Elgorashi et al., 2003);
micronucleus test and comet assay
(Taylor et al., 2003); and brine
shrimp toxicity assay (McGaw et al., 2007)
Sparg et al.
(2000)
Rosaceae
Leucosidea sericea Eckl.
& Zeyh.
L
S
CA –
in vitro
C. elegans 0.26
2.08
Negative – Ames test (Aremu et al., 2011) Aremu et al.
(2010a)
Rubiaceae
Canthium spinosum
(Klotzsch ex Eckl. &
Zeyh.) Kuntze
L CA –
in vitro
C. elegans 0.016 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Coddia rudis (E. Mey. ex
Harv.) Verdc.
L CA –
in vitro
C. elegans 0.008 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Conostomium natalensis
(Hochst.) Bremek.
L CA –
in vitro
C. elegans 0.270 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Lagynia lasiantha
(Sond.) Bullock
L CA –
in vitro
C. elegans 0.065 Negative – Ames test (Okem et al., 2012) Okem et al.
(2012)
Rutaceae
Clausena anisata (Willd)
Hook. f. ex Benth.
L DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
Zanthoxylum capense
(Thunb.) Harv.
L DBA –
in vitro
C. elegans 1.00 Negative – Ames test (Ndhlala et al., 2011) McGaw et al.
(2000)
Sapindaceae
Hippobromus pauciflorus
(L.f.) Radlk.
Ap DBA –
in vitro
C. elegans 0.50 Negative – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Solanaceae
Cestrum laevigatum
Schltdl.
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Nicotiana glauca
Graham
L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Sterculiaceae
Dombeya rotundifolia
(Hochst.) Planch.
Ap DBA –
in vitro
C. elegans 1.00 Negative — Ames and VITOTOX®
(Elgorashi et al., 2003); negative –
micronucleus test (Taylor et al., 2003);
and brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Thymelaeaceae
Gnidia capitata L.f. R DBA –
in vitro
C. elegans 1.00 Positive — brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
(continued on next page)
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Table 1 (continued)
Family
Plant species
aPlant
part(s)
bAssay
method
Test organism(s) cConcentration
(mg/ml)
Safety ﬁndings?
Method(s) and reference
Reference
Ulmaceae
Celtis africana N.L.
Burm.
– DBA –
in vitro
S. haematobium 50.0 Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); and positive –
micronucleus test (Taylor et al., 2003)
Sparg et al.
(2000)
Trema orientalis (L.)
Blume
Bk+wd DBA –
in vitro
C. elegans 1.00 Negative – Ames test (Hong and Lyu, 2011) McGaw et al.
(2000)
Urticaceae
Pouzolzia mixta Solms-
Laub.
L
S
DBA –
in vitro
C. elegans n/a
n/a
Negative – Ames and VITOTOX®
(Elgorashi et al., 2003); micronucleus test
and comet assay (Taylor et al., 2003); and
positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Verbenaceae
Clerodendrum glabrum
E. Mey.
L DBA –
in vitro
C. elegans 2.00 Unknown McGaw et al.
(2000)
Clerodendrum
myricoides (Hochst.)
Vatke.
L
S
CA –
in vitro
C. elegans 0.26
2.08
Positive – Ames test (Reid et al., 2006) Aremu et al.
(2010b)
Lantana camara L. L DBA –
in vitro
C. elegans n/a Negative – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Lantana rugosa Thunb. L DBA –
in vitro
C. elegans 1.00 Positive – brine shrimp toxicity assay
(McGaw and Eloff, 2005)
McGaw and
Eloff (2005)
Lippia javanica (Burm.f.)
Spreng
L+T DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
Vitaceae
Cissus quadrangularis L. S DBA –
in vitro
C. elegans n/a Positive – brine shrimp toxicity assay
(McGaw et al., 2007)
McGaw et al.
(2007)
Xanthorrhoeaceae
Aloe ferox Mill. L DBA –
in vivo
Strongyle
Trichuris spp.
Eimeria spp.
500 mg/kg Negative – bacterial and mammalian cell
genotoxicity assays (Andersen, 2007)
Maphosa and
Masika
(2012)
Aloe ferox Mill. L DBA –
in vitro
H. contortus 20.0 Negative – bacterial and mammalian cell
genotoxicity assays (Andersen, 2007)
Maphosa et al.
(2010b)
Aloe marlothii Alwin
Berger
L DBA –
in vitro
C. elegans 1.00 Unknown McGaw et al.
(2000)
a Plant part(s): Tb = tuber; Wd = wood; Wp = whole plant; Rm = rhizome; R = root; Rb = root bark; L = leaf; T = twig; Ap = aerial parts; Bk = bark; and C = corm.
b Assay method(s): DBA = Developmental and behavioral assay; and CA = colorimetric assay.
c Concentration (mg/ml): n/a = not active at highest concentration tested.
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available chemotherapies, there is a growing concern about
potential problems of acquired resistance as varying degrees of
resistance in nematode populations in humans and livestock have
been reported globally (Albonico et al., 2003; Jabbar et al., 2006).
As further emphasized by Kaplan and Vidyashankar (2012), the
‘inconvenient truth’ is that the development of anthelmintic
resistance will almost certainly eclipse the discovery of new
classes of anthelmintics. In fact, recent studies have indicated that
AADs are not active against relevant human STH such as
Necator americanus, Ancylostoma ceylanicum and Trichuris
muris (Tritten et al., 2011). In addition, the problem of re-
infection after chemotherapy (Kirwan et al., 2009), adverse drug
complications in certain groups of people such as hepatitis
patients, pregnant and lactating women (Savioli et al., 2003) have
been highlighted. For a long-time, the number of anthelmintic
drug research projects in academic laboratories and pharmaceu-
tical industries globally were limited (Geary et al., 1999a).
Although more effort has been recently geared toward the searchfor new anthelmintic, the quantity of work and outputs is
relatively small compared to other diseases such as cancer, HIV
and malaria. This is partially due to limited financial gains to the
multi-national pharmaceutical companies as the majority of
people who suffer from helminthiasis are the poor (Smout et al.,
2010). Researchers need to explore and validate novel solutions
or to rediscover ancient knowledge for a more sustainable control
of helminth diseases (Hoste and Torres-Acosta, 2011; Mrazek
andMossialos, 2003). The need to devote more efforts toward the
discovery of new anthelmintics of plant origin has been strongly
advocated (Athanasiadou et al., 2007;Waller et al., 2001). In fact,
the importance of plants as one of the natural sources of drugs
cannot be over-emphasized. An estimated 87% of the global
medications used against cancer, microbial and parasitic in-
fections are derived from natural products, particularly higher
plants (Newman et al., 2003). Since antiquity, humans have used
plants against ailments such as coughs, colds and parasitic
infections; probably based on trial and error (Gurib-Fakim,
2006).
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The use of plants and their extracts for the treatment of a
variety of human and livestock gastro-intestinal parasites have
been in existence for a long-time (Waller et al., 2001). Some of
the earliest known medicinal anthelmintic plants include
Carica papaya, Ficus species and Ananas comosus. Until
recently, anti-parasitic activity of most medicinal plants was
based on anecdotal evidence, but there is currently an increase
in the number of scientific studies aiming to verify, validate,
quantify and determine the safety of these plants (Athanasiadou
et al., 2007). Globally, scientists have intensified efforts in the
exploration of anthelmintics from natural products (Dornetshuber
et al., 2009; Koné et al., 2011; Kotze et al., 2009; Muthee et al.,
2011). On the positive side, anthelmintic compounds such as
santonin and filicic acids were isolated from Artemisia maritime
and Dryopterix filix-mas, respectively (Setzer and Vogler, 2006).
4.1. Contributions from South African researchers
In South Africa, medicinal plants have been used in the
treatment of parasitic diseases of both man and livestock for
centuries. The practice is still prevalent due to cultural reasons as
well as the relatively high cost and inaccessibility of the existing
chemotherapeutics (Clark et al., 1997). Evidence of the use of
South African plants is well documented in the commonly-used
literature (Hutchings et al., 1996; Watt and Breyer-Brandwijk,
1962) and researchers have investigated some of these South
African plants for their anthelmintic efficacy (Table 1). We
highlight 43 plant families consisting of 115 plant species that
have been investigated for their anthelmintic property. The
families included Combretaceae (21), Fabaceae (14), Asteraceae
(7), Apocynaceae (7), Verbenaceae (5), Euphorbiaceae (4) and
Rubiaceae (4) which accounted for more than 50% of the tested
species. Based on the findings from cited studies, about 57% of
the tested plant species exhibited various degrees of anthelmintic
activity (Table 1). Based on the in vitro test systems, examples of
South African plants with promising anthelmintic activity include
extracts from Markhamia obtusifolia (Nchu et al., 2011),
Tulbaghia violacea (McGaw et al., 2000), Combretum molle
(Ademola and Eloff, 2010), Hypoxis colchicifolia (Aremu et al.,
2010b), Cassinopsis illicifolia, T. riparia, and Coddia rudis
(Okem et al., 2012). In addition, Aloe ferox, Leonotis leonurus
and Elephantorrhiza elephantina (Maphosa and Masika, 2012)
have been shown to be effective anthelmintic remedies under in
vivo test systems.
Overall, the number of scientific reports in this field is small
compared to antimicrobial investigations (Fig. 1). In South
Africa, the continued neglect of anthelmintic studies is well
pronounced with 8-fold more antimicrobial papers compared to
anthelmintic papers published in South African Journal of
Botany (Fig. 1). Even though current data were not based on a
fully exhaustive and critical search of the entire database, it
gives the general trend. There is a need to stimulate more
interest and studies in this aspect of ethnopharmacology
(Mrazek and Mossialos, 2003; Torres-Acosta et al., 2012).
Particularly as helminthiasis is a serious problem to humans aswell as livestock production and the increasing risk of drug
resistance remains potentially detrimental (Patten et al., 2011).
Despite the limited available studies, some pharmacological
important compounds (e.g. butelinic and lupeol) exhibiting
anthelmintic have been isolated from South African medicinal
plants (Fig. 2). These compounds are also known for their
diverse biological activities (Gallo and Sarachine, 2009;
Yogeeswari and Sriram, 2005).
5. Anthelmintic activity assays and test-organisms
Helminths belong to a very large group of organisms that are
evolutionary diverse in body structure, biology and parasitic
mechanisms (Fennell et al., 2004; Geary and Thompson, 2001). It
is thus imperative to ask questions that may mar or make the
investigation. For instance, which test organism will be
employed? What type of test system is required — in vitro or in
vivo? In addition, important factors such as plant extracting
methods and the effect of environmental and seasonal variations
on the plant chemical composition, must be taken into
consideration when evaluating the potential of medicinal plants
for parasite control (Athanasiadou et al., 2007; Katiki et al., 2011).
These critical questionsmust be answered based on the aims of the
experiment, available equipment and financial resources. In vivo
and in vitro bioassays, as well as a number of test organisms, have
been employed to screen plants for anthelmintic activity (Table 1).
Both test systems and the varieties of organisms employed have
various limitations (Jabbar et al., 2006).
5.1. In vivo versus in vitro – benefits and drawbacks
As in the case with other pharmacological screening, it is
paramount to always use the ‘best practice’ approaches to
research into various disease states (Houghton et al., 2007). Most
preliminary screening investigations of plants for anthelmintic
activity utilize in vitro bioassays (Simpkin and Coles, 1981). As
evident in Table 1, the majority (approximately 96%) of the
studies in the current review were performed using in vitro
systems. Generally, the main advantages of using in vitro
bioassays include the low cost involved and rapid turnover that
allow for large-scale screening of plants, as well as the low
quantity of extracts required (Githiori et al., 2006; Whitfield,
1996). The weakness of in vitro tests is that researchers often
extrapolate results from in vitro tests to claim in vivo activity and/
or efficacy without taking into account vital factors such as
absorption and bioavailability. Ideally, in vitro bioassays should
be followed by in vivo tests when validating the anthelmintic
activity of medicinal plants (Athanasiadou et al., 2007).
However, it becomes relatively more expensive to screen plant
extracts on a large scale using in vivo studies. As a result, many
scientists are content with preliminary experiments culminating in
the numerous papers based on in vitro screening (Table 1).
Perhaps, better collaboration among local and international
researchers as well as more financial support from the government
and pharmaceutical companies would lessen the financial burdens.
Inevitably, this could stimulate the feasibility of either scaling-up
herbal mixture screening or the clinical trial of isolated compounds.
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Numerous test models such as the free-living nematodes
(Caenorhabditis elegans, Rhabditis pseudoelongata), earthworm
(Pheritima posthuma), ascarids (A. lumbricoides), rodent nema-
tode (Heligmosomoides polygyrus), trematode (Schistosoma
mansoni), cestode (Hymenolepis diminuta) and trichostronylid
(H. contortus) have been used in different studies (Githiori et al.,
2006). As observed in this review (Table 1) however, C. elegans
remains the most frequently used test organism. The organism
has long been employed for anthelmintic screening with limited
success especially, in terms of discovery of valuable new leads
(Geary et al., 1999b). Apparently, it is regarded as the most
suitable test organism for preliminary high-throughput in vitro
screening for compounds with broad spectrum nematocidal
activity (Geary and Thompson, 2001), being the best represen-
tative of a large phylum that contains several parasites (Bürglin et
al., 1998). C. elegans belongs to the Order Rhabditida, which is
closely associated with the Order Strongylida that contains the
important trichostrongyle nematode parasites of ruminants,
including H. contortus and Trichostrongylus spp. Furthermore,
the sensitivity of C. elegans to most commercial anthelmintic
drugs as well as the ease of culture growth and maintenance
contributes to its widespread use for anthelmintic screenings
(Katiki et al., 2011; Simpkin and Coles, 1981). H. contortus is
also commonly used as it is known for causing serious problems
in small ruminant production (Table 1). Despite the substantial
benefits derived from the use of C. elegans, a number of
limitations remain apparent (Geary and Thompson, 2001). There
is no single test organism without limitations thus; two or more
test organisms should be used for anthelmintic screening.
Besides, anthelmintics with a broad spectrum efficacy are of
more value and useful in the search for new compounds/drugs.
For instance, AADs were tested and proved effective against a
wide range of helminths such as C. elegans and H. contortus
(Ducray et al., 2008; Kaminsky et al., 2008b) but ineffective
against other STHs (Tritten et al., 2011).
5.3. Reappraisal of assay methods
Scientific evaluation or standards comparing the efficacy of
plant extracts to commercial anthelmintics, as well as
determining the level of anthelmintic activity are limited. As a
result, there is high experimental variability that has led to an
increased visible conflict of results on anthelmintic activity by
plant extracts (Athanasiadou et al., 2007). The discovery of new
anthelmintics relies to a certain extent on the availability of an
effective, rapid screening assay to detect anthelmintic properties
(Gnoula et al., 2007; Smout et al., 2010). Since the 1980s, the
importance of automated screening involving the use of a micro-
motility meter has been recognized (Bennett and Pax, 1986; Folz
et al., 1987). Despite the usefulness of the approach, the inherent
limitations restrict its application to small scale studies (Das et al.,
1988).
Researchers have employed different assays such as the larval
arrested morphology assay (LAMA), larval development assay
(LDA), larval motility assay (LMA), egg hatch test (EHT), adultdevelopment test (ADT), motility and colorimetric assays (Jabbar
et al., 2006; Kopp et al., 2008) to evaluate anthelmintic activity.
These various tests/assays can be partially divided into two major
categories: i) developmental and behavioral assays (DBA) and ii)
colorimetric assays (CA). In DBA, these anthelmintic studies
require measuring the survival and/or reproductive potential of the
worms after incubating with the test extracts for a specific time.
The efficacy of the tested extracts/compounds is often measured
based on the worms' viability (reproduction responses) or mobility
(behavior responses) after the incubation period (McGaw et al.,
2000). Basically, the worms are stimulated (if necessary) and
classified as either alive or dead/paralyzed. The efficacy is reported
based on the relative number of death and paralysis due to the
extract/drug compared to the controls. However, DBA are
generally subjective, often unreliable, time consuming and
laborious (Abdulla et al., 2009; Von Samson-Himmelstjerna et
al., 2009). In addition, it is always difficult to distinguish between
the paralyzed and dead worms (Gnoula et al., 2007). Thus, a
visual, qualitative and quantitative worm viability assessment was
developed (James and Davey, 2007).
In the CA methods, the test organisms are incubated with
extracts or conventional drugs for specific duration. Thereafter, the
metabolic activity is utilized as the measure of the test organism
viability after the addition of an indicator compound, e.g. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide-formazan
(MTT-formazan). Gnoula et al. (2007) also described a similar
method with the use of a different indicator, 5(6)-carboxyfluor-
escein diacetate (CFDA) which fluoresced dead worms. General-
ly, CA provides a simple method for viability testing in potential
anthelmintic plant extracts against C. elegans with the advantage
of rapid evaluation. Several South African medicinal plants were
screened with a modified CAmethod (Aremu et al., 2010a; Okem
et al., 2012). The use of p-iodonitrotetrazolium chloride (INT)
instead of MTT-formazan worked well due to the better stability
of INT. However, the use of CA is strictly only useful for in vitro
evaluation and seems to have some inherent limitations. For
instance, the use of response to indicators is likely to lead to loss
of some potential anthelmintic extracts and compounds with
moderate activity.
Recently, the successful application of a novel cell monitoring
device (xCELLigence, Roche Inc.) system for anthelmintic
screening was demonstrated (Silbereisen et al., 2011; Smout et
al., 2010). The technique assessed the real-time anti-parasite
efficacy of synthetic anthelmintics on eggs, larvae and adults in a
fully automated, label-free manner. It is a simple and objective
high-throughput assay for anthelmintics screening as well as
enabling resistance diagnosis by real-time monitoring of parasite
motility. The method is postulated to be valuable for the majority
of helminth species and developmental stages where EHA or
motility is used as a measure of worm viability. As recently
demonstrated however, xCELLigence systemmay only be useful
in the presence of adult hookworms (Tritten et al., 2012b).
Despite the shortcoming of xCELLigence system, the application
of this cutting-edge technology may be an invaluable tool for
exploring the rich South African botanicals. However, the high
cost could possibly hinder the availability of this cutting-edge
technology to researchers in developing countries.
Fig. 1. Elsevier-derived data comparing the frequency of antimicrobial and anthelmintic articles using different search parameters. GLB = global; SA = South Africa;
MP = medicinal plants; JEP = Journal of Ethnopharmacology and SAJB = South African Journal of Botany (only 2006–2012 available online). Data shown are only
meant to give an indication of the general trend rather than for comprehensive analysis purposes.
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A series of detailed systematic tests are basic and stringent
prerequisites before pharmaceutical companies release any
anthelmintic drug into the market. Thus, information on the
efficacy, mode of action, pharmacokinetic parameters and
potential environmental side-effects as well as the direct and
indirect toxicities of the drug is known. Conversely, similarH
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Fig. 2. Examples of anthelmintic compounds isolated from South Africa medicinal p
sericea (Bosman et al., 2004).information on plant extracts or herbal products are limited or
non-existent (Hoste and Torres-Acosta, 2011). The widely
held accepted belief and assumption are that natural products
are safe, based on their long-term usage by humans and
livestock (Verschaeve and Van Staden, 2008). Nevertheless,
recent investigations have revealed that some plants do have
mutagenic and perhaps toxic effects (Elgorashi et al., 2003;
Barlow and Schlatter, 2010). This raises concern about theO
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O
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lants. 1, 2 and 3 = Curtisia dentate (Shai et al., 2009); and 4 and 5 = Leucosidea
146 AO. Aremu et al. / South African Journal of Botany 82 (2012) 134–150potential mutagenic health hazards resulting from the long-term
use of such medicinal plants. Even though medicinal plants have
benefits such as low cost, availability and acceptability, their
safety and toxicity need to be evaluated and documented (Hoste
and Torres-Acosta, 2011; Street et al., 2008).
In order to distinguish a clearly toxic effect from pharmaco-
logical efficacy, it is appropriate to incorporate toxicity and/or
mutagenic tests when screening medicinal plants. Due to diverse
mechanisms responsible for toxic and mutagenic effects, the
importance of choosing the most appropriate and relevant safety
evaluation method cannot be overemphasized. Generally, the
Ames test is recommended for initial screening for mutagenic
potential due to its long history of usage as well as the proven
high degree of reproducibility of results and sensitivity
(Mortelmans and Zeiger, 2000). The Ames test was successfully
used to screen a wide range of South African medicinal plant
extracts (Verschaeve and Van Staden, 2008) and commercial
herbal mixtures (Ndhlala et al., 2010). The inclusion of S9
metabolic activation has been based on evidence that some
mutagenic plant extracts or compounds only exhibit their
mutagenicity after undergoing activation and transformation
by enzymatic and metabolic processes (Elgorashi et al., 2003;
Reid et al., 2006). Other commonly used safety evaluation
methods include the micronucleus test, comet and brine shrimp
assays with their inherent pros and cons. For example, the brine
shrimp assay is a simple, inexpensive technique for detecting
cytotoxic potentials; however, it remains ineffective when such
compounds required metabolic activation to become toxic
(McGaw et al., 2007). It is recommended that in vitro safety
evaluation should be followed by in vivo experiments for
confirmatory results.
6.1. Evaluation of the safety of South African plants used as
anthelmintics
Table 1 highlights the safety evaluation of common South
African medicinal plants with anthelmintic potential. In addition
to their promising anthelmintic activity, H. colchicifolia (Elgorashi
et al., 2003; Taylor et al., 2003) and A. dimiata (Brackenbury et al.,
1997) were shown to be safe whereas D. eriocarpum, B. zeyheri,
Gnidia capitata (McGaw et al., 2007), A. calamus (Padmaja et al.,
2002), Senna petersiana (Tshikalange et al., 2005) and Cleroden-
drum myricoides (Reid et al., 2006) are potentially unsafe due to
their toxic or mutagenic inducing effects. Furthermore, in other
plant species such as Acacia karoo (Adedapo et al., 2008), L.
leonurus (Maphosa et al., 2008) and Clematis brachiata (Afolayan
et al., 2009), the toxicity has been demonstrated to be dependent on
the concentration of the extracts. Unfortunately, limited scientific
data exist on the safety of other species such as Acokanthera
oppositifolia,Mondia whitei and Berkheya speciosa. Thus, caution
must be exercised when administering these plant extracts as
anthelmintic remedies for both humans and livestock.
7. Concluding remarks and future perspectives
Helminth infections affect a large proportion of the popula-
tion, especially those living in informal and rural settlements aswell as their livestock. There is also a growing resistance to the
available chemotherapeutics with frequent cases of reinfection
occurring. As with any class of drugs used against infective
pathogens, development of resistance to new AADs (latest class
of anthelmintics) remains a major concern (Prichard and Geary,
2008). Medicinal plants provide mixtures of many chemical
compounds possessing multiple biological activities. In South
Africa, the vast number of medicinal plants and the traditional
medicinal system remains poorly explored for anthelmintics.
Thus, appropriate screening and evaluation of more medicinal
plants with evidence of anthelmintic activity would offer
possible alternative remedies that are sustainable. Besides
validating the use of traditional medicines by providing a
homecare herbal remedy against helminth infection, it could
also serve as a preliminary phase in discovering leads for new
anthelmintics.
However, researchers have continued to neglect anthelmintic
investigation compared to other pharmacological properties such
as antimicrobial, anticancer and anti-HIV activities. In vitro
screening is important in validating the traditional use of medicinal
plants as well as for providing leads in the search for new active
principles. It could be a means of rapidly screening for potential
anthelmintic activity in medicinal plant extracts and providing
evidence for the possible mechanism(s) of the active compound(s).
More so, the number of isolated bioactive compounds demon-
strating anthelmintic activity is low.
Majority of the researchers have used the simplistic in vitro
assays. It is essential to remember that noteworthy pharmaco-
logical activity identified in in vitro test does not always directly
confirm that a plant extract is an effective medicine, or a suitable
candidate for drug development. In view of the differences
between in vitro and in vivo environments, active extracts should
be subjected to in vivo investigation with the use of different
parasitic test organisms. It is high time that we step out of the
comfort zone by advancing the preliminary studies to in vivo
systems, and ultimately clinical trials. Based on the inadequacy of
current screening methods, we need to critically review and
improve them for better efficiency. Finally, attempts at the
isolation and identification of bioactive compounds as well as
toxicity testing to determine the safety of the medicinal plants
should be pursued rigorously. We recommend more collabora-
tion among researchers both locally and internationally, the South
African government should also increase the funding and
incentives for scientists focusing on neglected diseases affecting
the poor. In addition, an increase in the number of quality studies
focusing on South African plants used as anthelmintics would
certainly contribute positively to this expanding ethnopharmaco-
logical field.Acknowledgments
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